Home/Filings/4/0001209191-19-053339
4//SEC Filing

SPECTOR STEVEN W 4

Accession 0001209191-19-053339

CIK 0001080709other

Filed

Oct 15, 8:00 PM ET

Accepted

Oct 16, 8:22 PM ET

Size

10.1 KB

Accession

0001209191-19-053339

Insider Transaction Report

Form 4
Period: 2019-10-14
SPECTOR STEVEN W
SVP, General Counsel & Sec
Transactions
  • Exercise/Conversion

    Common Stock

    2019-10-14+6,30015,990 total
  • Tax Payment

    Common Stock

    2019-10-14$47.32/sh3,123$147,78012,867 total
  • Exercise/Conversion

    Performance Restricted Stock Unit

    2019-10-146,30018,900 total
    Exp: 2022-01-03Common Stock (6,300 underlying)
Footnotes (3)
  • [F1]On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met.
  • [F2]Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs.
  • [F3]The amount reported in Column 7 of Table II represents the common shares that vested on October 14, 2019. Under the PRSUs, the Reporting Person has a contingent right to receive up to 18,900 additional common shares if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met.

Issuer

ARENA PHARMACEUTICALS INC

CIK 0001080709

Entity typeother

Related Parties

1
  • filerCIK 0001170362

Filing Metadata

Form type
4
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 8:22 PM ET
Size
10.1 KB